60 likes | 172 Views
Case presented by Dr Polkinghorn. 80 yo man: Active dancer, but weight loss & RUQ pain 5/10: USN = large masses in R liver biopsy ? “NSCLC”, but nonsmoker and no lung primary ↑AFP, re-eval of pathology = HCC (K-ras wt, EGFR-neg) Not a surgical candidate TACE x 3
E N D
Case presented by Dr Polkinghorn • 80 yo man: Active dancer, but weight loss & RUQ pain • 5/10: USN = large masses in R liver biopsy ? “NSCLC”, but nonsmoker and no lung primary • ↑AFP, re-eval of pathology = HCC (K-ras wt, EGFR-neg) • Not a surgical candidate TACE x 3 • At progression, offer sorafenib, but family declines • Patient expired just last week
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial Abou-Alfa GK et al. JAMA 2010;304(19):62154-60.
Ongoing Phase III Trials: HCC - Metastatic www.ClinicalTrials.gov, January 2011.
Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subgroup Analyses of the SHARP and Asia-Pacific (AP) Trials by Baseline Transaminase (ALT/AST) Alpha-Fetoprotein (AFP) and Bilirubin (Bil) Levels Raoul J et al. Proc ESMO 2010;Abstract 750P.
SHARP: Outcome by baseline LFTs/AFP Raoul J et al. Proc ESMO 2010;Abstract 750P.
Case presented by Dr Polkinghorn 80 yo man: Active dancer, but weight loss & RUQ pain 5/10: USN = large masses in R liver biopsy ? “NSCLC”, but nonsmoker and no lung primary ↑AFP, re-eval of pathology = HCC (K-ras wt, EGFR-neg) Not a surgical candidate TACE x 3 At progression, offer sorafenib, but family declines Patient expired just last week